Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Rani Therapeutics Holdings, Inc.

H.C. Wainwright analyst Brandon Folkes maintained a Buy rating on Rani Therapeutics Holdings today and set a price target of $11.00. According to T...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RANI	$0.76	+1.36%	382.40K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RANI	$0.76	+1.4%	382.40K
3
4
5
6

RANI

Get Rani Therapeutics Holdings, Inc. Data in Excel

Get Rani Therapeutics Holdings, Inc. Data in Excel